The role of plasma gelsolin in cardiopulmonary bypass induced acute lung injury in infants and young children: a pilot study

• Published in: BMC anesthesiology Vol. 14; no. 1; p. 67
• Main Authors: Shi, ShanShan, Chen, Chi, Zhao, DongYan, Liu, XiWang, Cheng, BaoLi, Wu, ShuiJing, Lin, Ru, Tan, LinHua, Fang, XiangMing, Shu, Qiang
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 07.08.2014; BioMed Central
• Subjects: Acute Lung Injury - blood; Acute Lung Injury - etiology; Analysis; Blood Proteins - analysis; Cardiopulmonary Bypass - adverse effects; Child, Preschool; Colleges & universities; Female; Gelsolin - blood; Hospitals; Humans; Infant; Infant, Newborn; Male; Measurement; Medical research; Medicine, Experimental; Pilot Projects; Plasma; Predictive Value of Tests; Respiratory distress syndrome; Risk Factors; Systemic Inflammatory Response Syndrome - blood; Treatment Outcome; Cardiopulmonary bypass; Acute lung injury; Young children; Infant; Congenital heart disease; Cardiac surgery; Plasma gelsolin
• ISSN: 1471-2253; 1471-2253
• DOI: 10.1186/1471-2253-14-67

Acute lung injury (ALI) induced by cardiopulmonary bypass (CPB, CPB-ALI) is a common and serious complication after cardiac surgery. And infants and young children are more prone to CPB-ALI. The purpose of this study was to investigate the perioperative changes of plasma gelsolin (pGSN) in patients below 3 years of age with cardiac surgeries and CPB, and determine whether pGSN are associated with the occurrence and severity of CPB-ALI. Seventy-seven consecutive patients ≤3 years of age with congenital heart diseases (CHD) performed on open heart surgery with CPB were finally enrolled, and assigned to ALI and non-ALI groups according to the American-European Consensus Criteria. Plasma concentrations of gelsolin and total protein were measured at following 8 time points: before CPB (a), after CPB (b), 2 hours after CPB (c), 6 hours after CPB (d), 12 hours after CPB (e), 24 hours after CPB (f), 48 hours after CPB (g) and 72 hours after CPB (h). Twenty-seven (35.1%) patients developed CPB-ALI in the study, including eleven (14.3%) patients with ARDS. The earliest significant drop of pGSN and normalized pGSN (pGSNN) of ALI group both occurred at 6 hours after CPB (p = 0.04 and p < 0.01), which was much earlier than those of non-ALI group (48 hours, p = 0.03 and 24 hours, p < 0.01); PGSN of ALI group before CPB and 6 hours after CPB were both significantly lower than those of non-ALI group (p < 0.01); PGSNN of ALI group before CPB and 6 hours after CPB were both significantly lower than those of non-ALI group (p < 0.01, p = 0.04); PGSN before CPB was the only independent risk factor predicting the occurrence of CPB-ALI (OR, 1.023; 95% CI, 1.007-1.039; p < 0.01) with an AUC of 0.753 (95% CI, 0.626-0.880); The optimal cutoff value of pGSN before CPB was 264.2 mg/L, with a sensitivity of 58.3% and a specificity 94.7%. And lower pGSN before CPB was significantly associated with the severity of CS-AKI (r = -0.45, p < 0.01). Patients developing CPB-ALI had lower plasma gelsolin reservoir and a much more amount and rapid consumption of plasma gelsolin early after operation. PGSN before CPB was an early and sensitive predictor of CPB-ALI in infants and young children undergoing cardiac surgery, and was negatively correlated with the severity of CPB-ALI.